Antipyrine elimination by patients under treatment with monoamine oxidase inhibitors.
1 Antipyrine elimination kinetics have been determined in fifteen patients before and after 4 weeks treatment with monoamine oxidase inhibitors and in five patients after treatment only. 2 Antipyrine elimination was slightly but significantly slowed by 28 days treatment with phenelzine but the degree of slowing was uninfluenced by acetylator phenotype or dosage of phenelzine administered. 3 The findings suggest that at the dosage used phenelzine is a weak inhibitor of hepatic microsomal mixed function oxidase in man and it is concluded that this is likely to provide an important source of drug interaction in some patients.
D000328:Adult; D000983:Antipyrine / Q000378:metabolism*; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects*; D010624:Phenelzine / Q000009:adverse effects / Q000627:therapeutic use; D010641:Phenotype
D008996:Monoamine Oxidase Inhibitors; D010624:Phenelzine; D000983:Antipyrine